King Pharmaceuticals and Acura Pharmaceuticals announced that King has submitted a New Drug Application (NDA) for Acurox (oxycodone HCl tablets) to the FDA, including a request for priority review classification. Acurox does not contain niacin. A separate NDA submission for Acurox with Niacin Tablets is subject to an FDA Complete Response Letter.
Acurox tablets utilize Acura’s patented Aversion Technology which is designed to deter opioid abuse by intravenous injection of dissolved tablets and nasal snorting of crushed tablets.
For more information call (800) 776-3637 or visit www.kingpharm.com.